ThromboGenics finishes patient enrollment in 2 drug trials

11/6/2009 | Reuters

Belgian biotech firm ThromboGenics finished enrolling patients in a U.S. Phase III trial of microplasmin, its candidate for back-of-the-eye disease. The company also concluded patient recruitment for a Phase II trial of TB-402, an experimental anti-clotting drug co-developed with Swedish firm BioInvent.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX